In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under clinical trial is pacibekitumab, an IL-6 ligand-blocking antibody.
According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, distinguished research scientist Fiona McDonnell, PhD, and Ian Pitha, MD, PhD, associate director of the Alan S. Crandall Center for Glaucoma Innovation
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.
According to presentations at FLORetina ICOOR 2024 in Florence, Italy, data show promising early improvements in low luminance visual acuity, a key measure of visual function. A pivotal Phase 2/3 VISTA trial for laru-zova in XLRP is currently enrolling.
A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD. At FLORetina ICOOR, he presented on a number of topics, including diabetic retinopathy—the subject of his conversation with the Eye Care Network.
According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.
Scott Hunter, who joined the company nearly 2 years ago, also had stints with Novartis, Shire, and Bausch + Lomb.
According to the company, VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.
Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients. Topline data is anticipated in 2026.
The Advanced Research Projects Agency for Health award has established a multidisciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation, with the goal of bringing sight to those who are blind through the first-ever successful vision recovery in 6 whole eye transplants in humans by 2030.
A team of Bascom Palmer Eye Institute and University of Miami researchers have received an award to fund the procurement, preservation, and transplantation of a human eye to restore vision.
PolyActiva’s phase 2 clinical trial of its PA5108 glaucoma implant met efficacy and safety end points, demonstrating more than 20% reduction in IOP. The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization offers free educational resources, including videos and guides, and supports GA patients through programs like Living Well With Low Vision.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
Welcome to the latest edition of This Week in Ophthalmology, a video series highlighting some of the top articles featured on the Ophthalmology Times website.
A Korean study identified preoperative use of preservative-containing glaucoma medications as a significant risk factor for trabeculectomy failure in POAG patients. The Glaucoma Medication Intensity Index (GMII) predicted long-term outcomes, highlighting the importance of managing medication exposure before surgery.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
Researchers at the University of Colorado Anschutz Medical Campus found that characters with crossed or drifting eyes are more likely to play more minor roles in animated movies and be considered unintelligent or villainous. These depictions, the researchers say, can have harmful effects for children with strabismus by perpetuating stereotypes.
In the wake of a report by a group of researchers in China detailing the increasing prevalence of myopia worldwide, Daniel Cyr, MD, a pediatric ophthalmologist at Stony Brook Medicine, agreed with its assessment, telling Ophthalmology Times he is seeing an increase in pediatric myopia at his clinic in New York.
In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in personalized ophthalmic care.
.png "Optometry Times"){kind=logo}
